Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
2022 is going to be the year of opportunities and innovations from the medical industry in India
The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles
Effectiveness of Covaxin against the Omicron variant is currently being studied
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
The company is focused on the development of novel treatments for RNA viruses
Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Subscribe To Our Newsletter & Stay Updated
